Dysbetalipoproteinemia Clinical Trial
Official title:
Dysbetalipoproteinemia and Atheroma Risk : Assessment of Cardiovascular Risk in Dysbetalipoproteinemic Patients
Dysbetalipoproteinemia (type III, Fredrickson's classification) is a rare metabolic
disorder. It results from a defect in the clearance of VLDL and chylomicron remnants due to
homozygous APOE2 variants or heterozygous APOE mutations, and there is an elevated plasma
cholesterol and triglycerides.
As a consequence of the derangements in lipoprotein metabolism, dysbetalipoproteinemia
predispose to the premature development of atherosclerosis.
However among this population there is heterogeneity in development of cardiovascular
complications and the determinants remain unclear actually.
The aim of the investigators study is to evaluate the intensity of clinical atherosclerosis,
and identify its determinants.
n/a
Observational Model: Cohort, Time Perspective: Prospective